Verona Pharma PLC
NASDAQ:VRNA

Watchlist Manager
Verona Pharma PLC Logo
Verona Pharma PLC
NASDAQ:VRNA
Watchlist
Price: 86 USD Market Closed
Market Cap: 7.4B USD

During the last 3 months Verona Pharma PLC insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 19% over this period (open performance analysis).

The last transaction was made on Aug 1, 2025 by Ebsworth David R , who sold 25k USD worth of VRNA shares.

Last Transactions:
Cunningham Kenneth
$-142.1k
Deschamps Lisa
$-124.4k
Fisher Andrew
$-126k
Rickard Kathleen A.
$-766.8k
Ackermann Christina
$-23.8k
Austwick Michael
$-148.4k
Edwards Martin
$-142.1k
Brady James Aloysius
$-10.8k
Zaccardelli David
$-2.7m
Hahn Mark W
$-2.7m
Sinha Vikas
$-56.9k
Shah Mahendra
$-47.4k
Ebsworth David R
$-25k
Fisher Andrew
$-922k
Zaccardelli David
$-4.6m
Hahn Mark W
$-4.6m
Zaccardelli David
$-1.9m
Hahn Mark W
$-1.9m
Zaccardelli David
$-1.5m
Hahn Mark W
$-1.5m
Zaccardelli David
$-320.2k
Hahn Mark W
$-309k
Sinha Vikas
$-1.5m
Fisher Andrew
$-685.6k
Ackermann Christina
$-337.6k
Rickard Kathleen A.
$-1m
Zaccardelli David
$-3.6m
Hahn Mark W
$-3.6m
Rickard Kathleen A.
$-244.7k
Hahn Mark W
$-969.1k
Zaccardelli David
$-969.1k
Sinha Vikas
$-134.2k
View All Transactions

During the last 3 months Verona Pharma PLC insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 19% over this period (open performance analysis).

The last transaction was made on Aug 1, 2025 by Ebsworth David R , who sold 25k USD worth of VRNA shares.

Sold
0-3
months
0 USD
0
3-6
months
17.1m USD
13
6-9
months
24.5m USD
6
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
0
0 USD
6-9
months
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

Verona Pharma PLC
Insider Trading Chart

Verona Pharma PLC
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Verona Pharma PLC
Last Insider Transactions

Global
Insiders Monitor

Verona Pharma PLC
Glance View

Market Cap
7.4B USD
Industry
Pharmaceuticals

Verona Pharma PLC, an ambitious player in the biopharmaceutical arena, is woven into the intricate tapestry of the healthcare industry, focusing its energies on respiratory ailments. Born within the thriving biopharma sector in London, this company has targeted chronic obstructive pulmonary disease (COPD) with its novel therapies, driven by the urgent need to alleviate this global burden. The company's flagship product, ensifentrine, serves as a dual inhibitor of the enzymes phosphodiesterase 3 and 4, aiming to enhance lung function and ease the constriction challenges faced by patients. Through strategic clinical trials and robust scientific inquiry, Verona Pharma seeks not only to innovate in treatment but also to deliver tangible hope for those grappling with chronic respiratory conditions. Verona Pharma's business model is anchored in advancing its drug development pipeline, propelled by a blend of scientific rigor and strategic partnerships. It capitalizes on patent protection and licensing agreements to secure its financial footing, investing heavily in research to drive value creation. The company earns its revenue predominantly from collaborative agreements with larger pharmaceutical entities, milestone payments, and potential royalties upon successful commercialization of its therapies. Through aligning with other industry giants, Verona Pharma not only financially fortifies its pursuits but also accelerates the dissemination of its therapeutic innovations, ensuring that their beneficial impacts reach as many patients as possible. This harmonized approach with partners places Verona Pharma on a trajectory not just of financial growth but also of achieving its underlying mission – transforming the landscape of respiratory disease management.

VRNA Intrinsic Value
60.72 USD
Overvaluation 29%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top